Pepper Bio’s Post

Our co-founders, Jon (Yu) Hu and Samantha Dale Strasser, started Pepper Bio to find treatments for untreatable diseases. Today, we’ve reached a significant milestone toward that mission through our deal with G1 Therapeutics, Inc. for lerociclib. Hepatocellular carcinoma (HCC), the most common type of liver cancer, is the third leading cause of all cancer-related deaths. Our platform, COMPASS, has identified lerociclib to be an efficacious therapeutic in treating HCC, and subsequent testing in pre-clinical in vivo models showed superior efficacy over current options during and after dosing. Read more about the deal and what’s next for Pepper Bio via James Waldron in Fierce Biotech: https://lnkd.in/dAPgc3av

We're excited to announce that Pepper Bio is launching a collaboration to increase understanding of healthy muscle growth with Novo Nordisk’s Bio Innovation Hub through its Co-Creation Greenhouse Program. Founded by MIT and Havard alumni, Pepper Bio integrates genomic, transcriptomic, proteomic, and phosphoproteomic data into a transomic activity signature to answer complex biological questions. Using Pepper Bio’s COMPASS transomic platform, we will conduct research to create a transcriptomic signature characteristic of healthy muscle growth, eventually leading to possible functional muscle. COMPASS has validated capabilities in identifying targets, untangling the drivers of disease, and profiling novel modalities. This collaboration with the #BioInnovationHub provides Pepper Bio with funding and access to Novo Nordisk scientists.

Transomics + AI is the recipe needed to uncover new therapeutic possibilities. It’s how we identified lerociclib as a promising therapeutic for liver cancer. Today, our CEO Jon (Yu) Hu gives a deep dive into the process that led to this discovery in Drug Target Review. Read his full Q&A here: https://lnkd.in/eX6MyH3U #Transomics #DrugDiscovery 

Day 1 of Reuters Pharma USA 2024 begins! Our very own Caitlin Brown will be taking part in this pharma gathering, looking forward to in-depth conversations around AI in drug discovery and precision medicine for optimal patient outcomes. Are you attending this year’s event? Let us know and let’s connect! #REpharmaUSA #Biotech #DrugDiscovery #AI

AI continues to be a hot topic in biotech, but let’s not forget the challenges that come with advanced technology. AI is not a magic cure, but a powerful tool that, combined with human expertise, can lead to significant advancements in treating diseases. The real magic happens when we blend AI's analytical capabilities with the insights of scientists to tackle untreatable diseases more effectively. More insights from STAT’s Casey Ross here: https://lnkd.in/dT6upRpt #AI #DrugDiscovery #UntreatableDiseases

Great to see promising developments in the world of biotech! Leveraging machine learning capabilities, the UVA Cancer Center has developed a method to identify high-risk acute myeloid leukemia (AML) patients using bioactive molecules in cancer cells. One size does not fit all. Personalized solutions enable treatments to be specifically designed to match an individual's unique genetic makeup, leading to more effective and safer healthcare outcomes. More on UVA’s discoveries here: https://lnkd.in/gBYNvnKv #DrugDiscovery #AML #AI #ML

Let the countdown begin! CEO Jon (Yu) Hu will be on the LSX World Congress panel speaking on optimizing AI in the biotech and pharma space. Will you be attending LSX? If so, let’s connect! #Biotech #AI #LSX

The FDA’s approval of repotrectinib targets the ROS1 fusion in non-small cell lung cancer—heralding a new era in cancer therapy that emphasizes precision and genetic specificity. It’s a stride that resonated with our ethos of trailblazing patient-specific treatments, reaffirming the promise of precision medicine in transforming lives. Learn about this innovative approach to lung cancer treatment here: https://lnkd.in/gdk4MNX5 #DrugDiscovery #LungCancer #PrecisionMedicine #Biotech

🧬Massive thank you to the HealthTechX Global Awards for selecting Pepper Bio as a finalist in the Innovator category! We remain committed to progressing towards a future where the label "untreatable disease" becomes obsolete. Congratulations to all the other companies on the shortlist! CC: Samantha Dale Strasser, Jon (Yu) Hu, Caitlin Brown, Dr. D. Martin Alexander Gershon, MD, JD, MPH, Chris Nicholson, Simon Fricker, Samuel Roth, Arudhir Singh,VSC #DrugDiscovery #AI #PepperBio